Molindone Dosage

Medically reviewed by Drugs.com. Last updated on Aug 9, 2023.

Usual Adult Dose for Schizophrenia

Initial Dosing Schedule:

• Recommended dose: 50 to 75 mg orally per day, increasing the dose to 100 mg/day in 3 to 4 days
• Maximum dose: 225 mg/day

Maintenance Dosing Schedule:

• Mild symptomology: 5 to 15 mg orally 3 to 4 times a day
• Moderate symptomology: 10 to 25 mg orally 3 to 4 times a day
• Severe symptomology: Up to 225 mg/day

Comments:

• Patients with severe symptomology may require 225 mg/day.
• Elderly and/or debilitates patients should begin on the lower dosage.

Use: Management of schizophrenia

Usual Pediatric Dose for Schizophrenia

12 to 18 years:
Initial Dosage Schedule:

• Recommended dose: 50 to 75 mg orally per day, increasing the dose to 100 mg/day in 3 to 4 days
• Maximum dose: 225 mg/day

Maintenance Dosing Schedule:

• Mild symptomology: 5 to 15 mg orally 3 to 4 times a day
• Moderate symptomology: 10 to 25 mg orally 3 to 4 times a day
• Severe symptomology: Up to 225 mg/day

Comments:

• Patients with severe symptomology may require 225 mg/day.
• Debilitated patients should begin on the lower dosage.

Use: Management of schizophrenia

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

US BOXED WARNING:

• INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS: This drug has an increased risk of mortality when administered to elderly patients with dementia-related psychosis. Elderly patients with dementia-related psychosis treated with antipsychotic drugs have an increased risk of death. This drug is not approved for use in patients with dementia-related psychosis.

Safety and efficacy have not been established in patients younger than 12 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• See manufacturer product information.

Storage requirements:

• See manufacturer product information.

General:

• Effectiveness was determined in clinical studies with newly hospitalized and chronically hospitalized, acutely ill patients with schizophrenia.
• This drug has not been shown effective in the management of behavioral complications in patients with mental impairment.

Monitoring:

• Complete blood count before and periodically during treatment

Patient advice:

• Warn patients to avoid abrupt discontinuation of this drug.
• Tell patients to immediately report any signs/symptoms of neutropenia/leukopenia, neuroleptic malignant syndrome, or tardive dyskinesia.
• Patients should be advised to report all concurrent prescription and nonprescription medications or herbal products they are taking.
• Inform patients that this drug may cause drowsiness, and they should avoid driving or operating machinery until the full effects of the drug are known.
• Patients should be advised to speak to a healthcare provider if they are pregnant, intend to become pregnant, or are breastfeeding.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer